Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab observational cohort in rheumatoid arthritis with lipid profile monitoring
NL-OMON36406Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of golimumab in rheumatoid arthritis (RA), sponsored by Jan van Breemen Institute. Primary endpoints: Efficacy versus baseline, Radiological progression and 3 more. Started Mar 2011; status: recruiting.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36406.